#read

Merck records strong growth in the third quarter of 2024

The technology company Merck achieved solid organic growth in the third quarter. Sales increased by 3.8% to € 5.3 billion, while EBITDA pre exceptionals grew organically by 16.9% to € 1.6 billion. The EBITDA margin pre exceptionals improved significantly to 30.7%. All business sectors contributed to this positive development, meaning that Merck remains on track to be profitable in 2024 as a whole.

04/12/2024

In the Life Science business sector, Merck returned to organic growth. Sales revenues increased by 2.1% to 2.2 billion euros, supported by a recovery in Science & Lab Solutions (+4.3%) and Process Solutions (+3.7%). Declines in Life Science Services due to the one-off effect of Covid-19 in the previous year were offset by efficiency measures and positive developments in other areas. EBITDA pre exceptionals increased by 7.1% to 646 million euros.

Healthcare achieved strong organic sales growth of 6.2% to 2.1 billion €. Growth was driven by the multiple sclerosis drug Mavenclad (+19.8%) and the cancer drug Erbitux (+13.8%). Other segments such as cardiovascular and endocrinology also developed positively. EBITDA pre exceptionals rose organically by an impressive 27% to EUR 836 million and achieved an excellent margin of 39.2%.

The Electronics division continued its profitable growth trajectory. Sales increased organically by 2.4 per cent to 923 million euros, primarily thanks to Semiconductor Solutions (+7.0 per cent), which benefited from the high demand for materials for modern semiconductors and AI applications. EBITDA pre exceptionals rose by 15 per cent to 235 million euros, with a margin of 25.5 per cent.

Merck confirms its forecast for the 2024 financial year and expects organic sales growth of between 2% and 5% (20.7 to 22.1 billion euros). EBITDA pre is expected to increase organically by 4% to 10% (5.8 to 6.4 billion &euros;), while earnings per share (EPS pre) should be between 8.20 and 9.30 &euros;. Despite possible negative currency effects, Merck believes it is well positioned to benefit from the robust market trends and to further expand its cross-sector portfolio. These results underline Merck's strength and innovative power in a challenging global market environment.

News von "Merck" vom 14.11.2024

The above texts, or parts thereof, were automatically translated from the original language text using a translation system (DeepL API).
Despite careful machine processing, translation errors cannot be ruled out.

Click here to access the original content